Evotec

Update in progress

EVO (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Evotec SE is a drug discovery and development company with operations in the US, Europe, and beyond. It has two segments, Shared R&D and Just Evotec Biologics, and develops products across oncology, autoimmune, metabolic, cardiovascular, CNS, infectious, kidney and liver diseases, fibrosis, rare diseases, and animal and women’s health. It collaborates with leading institutions and pharma partners worldwide. Headquartered in Hamburg, Germany; founded in 1993 (formerly Evotec AG).

Company score

Sentiment: 0.23; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.39; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.10; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.19; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive